国海证券曾发研报指，基于TransCon技术的长效生长激素隆培预计上市在即，其相比于短效人生长激素显示出优效性及同等安全性。隆培生长激素为维昇药 业于2018年11月自Ascendis Pharma授权引入，凭借TransCon"暂时连接技术"长效路径，隆培生长激素是唯一一款于每周给药之间在体内持续释放未经修饰的 人生长激素的长效生长激素，经已完成的中国Ⅲ期关键性试验所验证，隆培生长激素是唯一一款在与短效人生长激素的阳性药物对照及平行组试验比较中显 示出优效性及同等安全性的长效生长激素。(格隆汇) 消息面上，Insight数据库显示，维昇药业-B核心产品隆培促生长素已于2026年1月12日离开补充资料任务，预计即将获批。据悉，隆培促生长素是维昇药业- B从Ascendis Pharma引进的长效生长激素前药，是全球首个在美国及欧洲获批用于儿童生长激素缺乏症(GHD)的长效周制剂。国内生长激素市场以日制剂为 主，周制剂可大幅提升患者依从性，上市后有望重塑竞争格局，满足未被充分满足的临床需求。 维昇药业-B(2561.HK)今日高开高走，盘中一度大涨9.9%至38.2港元，股价创去年12月19日以来逾一个月新高。 ...

Core Viewpoint - Guohai Securities reports that the long-acting growth hormone, Lonpei, based on TransCon technology, is expected to be launched soon, demonstrating superior efficacy and equivalent safety compared to short-acting growth hormones [1] Company Summary - Lonpei growth hormone was introduced by Weisheng Pharmaceutical in November 2018 through a licensing agreement with Ascendis Pharma [1] - The growth hormone utilizes TransCon (transient conjugation technology) for long-acting delivery, making it the only long-acting growth hormone that continuously releases unmodified human growth hormone between weekly doses [1] - Completed Phase III pivotal trials in China have validated that Lonpei is the only long-acting growth hormone showing superior efficacy and equivalent safety in comparison to short-acting growth hormones in positive drug control and parallel group trials [1] - Weisheng Pharmaceutical anticipates that Lonpei will receive domestic approval for marketing in the fourth quarter of 2025, suggesting that investors should closely monitor the company in the near term [1]